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The Alere Afinion™ AS100 analyser is a compact bench-top, multi-assay, point-of-care (POC) analyser that 
provides valuable near patient testing at the point of care. It utilises the latest technology to measure C-Reactive  
Protein and other analytes to monitor patients’ disease progression. The main objective of the study was to evaluate 
the performance of the Alere Afinion™ AS100 analyser compared with a reference laboratory test method, ABX 
Pentra 400 for the measurement of C-Reactive Protein (CRP).   
  
Methods  
This study was a retrospective analysis in which stored serum samples obtained from a cross-sectional study referred 
to as Sexual Health, HIV infection and comorbidity with non-communicable diseases among Older Persons 
(SHIOP) were tested for the quantification of the CRP. The primary aim of SHIOP was to describe sexuality, sexual 
health and the comorbidity of HIV and sexually transmitted infections with chronic non-communicable diseases in 
adults aged ≥50 years in a setting of high HIV prevalence. Serum stored at -20 ⁰C from participants that consented 
to long term storage(n=183) was used to perform this evaluation.  The serum samples were used to measure CRP 
on the Alere Afinion™ AS100 and ABX Pentra 400, respectively. Lin’s correlation coefficient was used to assess 
the agreement between the two analysers for the measurement of CRP. Risk factors associated with elevated CRP 
levels were assessed through this study.    
 
Results  
A total of 183 serum samples were tested in the study. The mean age of the study participants was 7.62 years (SD 
8.15). Male participants were slightly older than female participants (61 vs 58years, p<0.05). Approximately 14.2% 
of study participants were above 70 years of age.  The study population consisted of 77/183 (42%) Black South 
Africans and 106/183 (57.9%) Indians. The Alere Afinion™ AS100 was able to correctly classify (165/183) >90% 
of the CRP results when compared to the ABX Pentra 400. Bland-Altman analysis and linear regression analysis 
showed an excellent agreement (correlation concordance 0.97) between the two analysers. This study showed that 
being obese (Odds Ratio [OR]: 1.98, 95% Confidence Interval [CI]: 1.3616, 2.889, p<0.001) and having low HDL 
levels (OR: 1.64, 95% CI: 1.158, 2.307, p= 0.005) were the only significant risk factors that were associated with 
elevated CRP levels.  
 
Conclusion  
This study showed that the Alere Afinion™ AS100 can be used for the measurement of CRP in instances where 
CRP is greater than 5mg/L and this may enhance the process of patient care and management in low resource 
settings.   
 
Keywords: C-Reactive Protein (CRP), Affinion AS100, Sexual Health, HIV infection and comorbidity with non-
communicable diseases among Older Persons (SHIOP), ABX Pentra 400.  
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CHAPTER ONE  
  
1.0 INTRODUCTION  
 
Non-Communicable Diseases (NCDs) are by far the leading cause of mortality globally (Gowshall et al., 2018). An 
even higher proportion (75%) of premature adult deaths (occurring in those aged 30–69 years) were caused by 
NCDs, demonstrating that NCDs affect a wide age range of the global population (Global Status Report on Non-
communicable Diseases, 2018). The global probability of dying from one of the four main NCDs (CVDs e.g. heart 
attacks  and stroke ), cancer, chronic respiratory attacks and stroke), cancer, chronic respiratory diseases (such as 
chronic obstructed pulmonary disease and asthma] and diabetes) in 2016 was 18%, with a slightly higher risk  of 
22% for males as compared to 15% for females (World Health Organization, Global Status Report on Non-
Communicable Diseases, 2018). According to the Global Burden of Diseases, Injuries, and Risk Factors Study 
GBD, 2016, deaths due to NCDs are projected to rise from 38 million to 52 million by 2030 (Global Status Report 
on Non-Communicable Diseases, 2014). These statistics demand that focus be directed not only to infectious 
diseases but to NCDs as well (Global Status Report on Non-Communicable Diseases, 2014). 
 In 2016, the cause of approximately 17.6 million (95% CI, 17.3–18.1 million) global mortalities were due to CVDs 
with a documented increase of 14.5% (95% CI, 12.1%–17.1%) over a 10-year period (2006-2016) (Benjamin et al., 
2019). Findings from the INTERHEART Africa study indicated that the highest number of premature acute 
myocardial infarctions (AMI) occurred in sub-Saharan Africa (Steyn et al., 2005). This is due to lack of early 
detection and effective management of risk factors (South African Dyslipidaemia Guideline Consensus Statement, 
2012). Hypertension, diabetes, and hyperlipidaemia were reported to be risk factors for CVDs (Cojocaru et al., 
2017). Nearly 50% of deaths resulting from heart disease could be avoided by management of the risk factors 
(hypertension, hyperlipidaemia and increased body weight (Cojocaru et al., 2017). 
In addition to HIV, hypertension is highly prevalent in South Africa (Lloyd-Sherlock, 2014). A past study on 
hypertension in older individuals reported that 78% of South African adults older than 50 years of age, suffered 
from hypertension (Lloyd-Sherlock et al., 2014). The study by Peltzer and Mafuya, 2013 on hypertension and 
associated factors in older adults in South Africa also revealed that older South Africans (50 years and above) are 
at high risk of CVDs due to high rates of hypertension. According to Peltzer and Mafuya, 2013, of the large 
proportion of older people who were aware of their condition only a few were treated. Therefore, there is an urgent 
need for public health education and the implementation of systems to monitor NCDs and their risk factors such as 
hypertension (Peltzer and Mafuya, 2013).  
 
Evidence has shown that C-Reactive Protein (CRP) levels are able to predict the risk of a variety of cardiovascular 
outcomes such as AMI, sudden cardiac death and peripheral arterial disease. CRP levels have also been shown to 
predict the risk of intermittent ischaemia, acute coronary syndrome and percutaneous angioplasty among individuals 
with stable and unstable angina (Sarkar et al., 2019). Evidence indicates that plasma levels of CRP and other 
sensitive biomarkers of systemic inflammation may be interrelated with imminent probability of coronary heart 
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disease (CHD) in the general population (Slaats et al., 2016). Baseline concentrations of CRP and other biomarkers 
of low-grade inflammation are associated with chronic progressions possibly connected to CHD (Slaats et al., 2016). 
CRP plays an important role against bacterial infections and during inflammation (Sproston et al., 2018). A previous 
study from South Africa revealed that there is a close association between obesity and inflammation as well as a 
close link between cardiovascular function and inflammation (Schutte et al., 2006). Inflammation is thought to 
contribute to atherogenesis and disease development, and the inflammatory cascade is distinctly vital in the process 
of atherosclerosis (Welsh et al., 2017). Due to the fundamental role that inflammation plays in disease development 
and atherogenesis, anti-inflammatory treatments may assist in preventing cardiovascular events (Welsh et al., 2017). 
Menon et al., 2003 revealed that CRP levels were independently associated with serum albumin level and CVD 
prevalence.  
Studies conducted by Biasucci et al., 2000 and Sakkinen et al., 2002 showed that CRP was a significant predictor 
of CVDs among participants with or without diabetes. In another study, Jager et al., 1999 investigated the 
association of CRP with CVDs and all-cause mortality among participants with and without diabetes. This study 
involved a population of (n=631) participants aged from 50 to 75 years. The study included a prospective follow up 
for 5 years. The study revealed that after 5 years of follow up, 58 participants had died, and 24 of those deaths were 
attributed to CVDs.  However, Jager et al., 1999 found no association between CRP levels and cardiovascular death 
in participants with and without diabetes.  
A previous study has shown that there is a close link between elevated serum CRP levels and increased vulnerability 
for disease and mortality in older patients (Velissaris et al., 2017). Due to its involvement in the whole process of 
CVD from the formation of fatty elements to the actual clinical occurrences, CRP has been found to be comparable 
to other confirmed cardiovascular risk factors namely, diabetes and hypertension (Bisoendial et al., 2010). CRP has 
recently been used as the independent tool to enhance certainty in the diagnosis process (Lemiengre et al., 2018). 
The high mortality rates associated with cardiovascular events is caused by challenges faced by most patients such 
as access to laboratory testing facilities, or the unavailability of these facilities to quickly identify biomarker risk 
factors (Sharma et al., 2015). Most developing countries often lack laboratories with state-of-the-art automated 
analysers that offer laboratory results that are highly reproducible, accurate and highly sensitive (Sharma et al., 
2015). Most primary care health centres (PHCs) do not have laboratories. When medical doctors require blood 
results to make a clinical diagnosis, biological samples are usually sent to a central laboratory that is sometimes a 
great distance from the clinic (Stone et al., 2007). This leads to delays such as patient counselling and treatment. 
Clinics in rural areas with limited resources do not house basic diagnostic equipment and there is a shortage of 
trained staff.  
Delivering healthcare in these areas is a major challenge due to unavailability of clean running water and dependable 
electrical services (Mcnerney and Daley, 2011).  In order to overcome these limitations, it is crucial that fast and 
easy to use point of care tests (POCTs), that can significantly increase clinicians’ proficiency to identify patient 
diseases quickly and accurately be implemented. POCTs have the ability to provide rapid results thus improving 
patient management (Stone et al., 2007, Mogensen et al., 2011). 
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Point of care (POC) testing is defined as testing of patient biological specimens in a setting outside a normal clinical 
laboratory. This is usually near bedside or at the site of patient care. POC testing is usually performed by clinical 
staff that have not undergone laboratory training, however it can also form part of patient self-monitoring (Fiallos 
et al., 2001).  
The advantages of POCTs over standard laboratory testing is that there is no need for expensive laboratory 
equipment and highly trained laboratory staff to operate the instrument (Florkowski et al., 2017). Additional 
advantages include: POC testing also assists in reducing time-dependent variations for certain analytes which can 
deteriorate due to delays during sample transportation to the clinical laboratory and (smaller sample volumes are 
used for POC testing when compared to standard laboratory tests (Fiallos et al., 2001). This makes POC testing a 
method of choice for most clinicians (Kazmierczak, 2011). There is an increase in demand for patients seeking 
treatment at local clinician’s offices and this has contributed to POCTs becoming one of the fastest growing areas 
of biomedical technology (Kazmierczak, 2011). Jain et al., 2016 confirmed that the Afinion™ AS100 analyser 
provided a platform for the analysis of multiple analytes with good comparability to the standard laboratory method. 
Kvam et al., 2009, also found that the Afinion™ AS100 was able to produce a good correlation when compared to 
another POCT DCA 2000 for Microalbumin/ Creatinine as well as when compared to the automated laboratory 
modular albumin and creatinine methods. Abbai et al., 2018 recently found a good correlation between the Alere 
Afinion™ AS100 analyser and the ABX Pentra 400 analyser for the measurement of glycosylated haemoglobin and 
lipid levels in older adults in Durban, South Africa. This study provided the first report on the diagnostic 
performance of the Alere Afinion™ AS100 in quantifying CVD biomarkers in a population of older persons aged 
50 years and above, which included both HIV uninfected and HIV infected individuals in the KwaZulu-Natal 
province. This study supported the utilisation of the Alere Afinion™ AS100 as a POCT for quantification of 
HbA1C, triglycerides and high-density lipoprotein (HDL) in a South African setting.    
Of all the above-mentioned studies, none have evaluated the diagnostic performance of the Afinion™ AS100 
analyser when compared to standard laboratory tests for the determination of CRP levels in a population of older 
men and women. Hence the need for the present study. The purpose of the present study was to evaluate the Alere 
Afinion™ AS100 analyser (Alere, South Africa) against the ABX Pentra 400 analyser for the measurement of CRP 
levels. In addition, the study will provide data on the prevalence and risk factors of CVDs in older men and women 












2.1 EPIDEMIOLOGY OF NON- COMMUNICABLE DISEASES (NCDs) 
Globally, Non-Communicable Diseases (NCDs) are responsible for the largest portion of mortalities, contributing 
to 73.4% (95% uncertainty interval [UI] 72.5–74.1) of total deaths in 2017 (Roth et al., 2018). The total numbers of 
deaths due to NCDs increased by 22.7% (21.5–23.9) from 2007 to 2017, indicating a further 7.61 million (7.20–
8.01) mortalities in 2017 (Roth et al., 2018).  
NCDs are responsible for an estimated 17.0 million (57%) of the 29.8 million deaths in people below 70 years of 
age, which is the age generally used to identify premature death (Di Cesare et al., 2013). Premature death has 
become a major challenge when weighing the effect of NCDs on a given population, with nearly 44% of all NCD 
mortalities occurring prior to the age of 70 years (Ediriweera et al., 2018). A large proportion (82%) of all premature 
NCD mortalities occur in low- and middle-income countries, (Di Cesare et al., 2013, Nethan et al., 2017, Ediriweera 
et al. 2018).  
In low- and middle-income countries, a higher proportion (48%) of all NCD mortalities are reported in people below 
the age of 70 years, when compared with high-income countries (26%). Additionally, in low- and middle-income 
countries, 29% of NCD mortalities occur among people under the age of 60 years, compared to 13% in high-income 
countries (World Health Organisation, 2011). Low-and lower-middle-income nations are expected to see 
remarkable rises in the burden of premature mortality and frailty from NCDs by 2040 (Bollyky et al., 2017). 
According to the NCD Countdown 2030 collaborators 2018 report, approximately 25% of deaths in persons older 
than 10 years of age were due to NCDs. More than 50% of these deaths occurred in people older than 40 years of 
age (Figure 1). Additionally, 13.3 million (56%) deaths attributed to NCDs occurred in people aged 80 years and 
older (Bennett et al., 2018). According to findings presented in Figure 1, NCDs are responsible for a considerable 
portion of deaths in both men and women aged 45 years and above with cardiovascular diseases (CVDs) and 
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Figure 1: Global number of deaths in 2016 from Non communicable diseases (NCDs), injuries, communicable 
disease, maternal, perinatal and nutritional conditions (NCD Countdown 2030 collaborators, 2018).  
 
 
2.2 NON-COMMUNICABLE DISEASES AND CARDIOVASCULAR DISEASES 
CVDs remain a key public health challenge globally (Boateng et al., 2018). A large proportion (80%) of mortalities 
due to CVDs occur in low- and middle-income countries with similar rates in both males and females (Benjamin et 
al., 2017). In 2013, CVDs were the most common underlying cause of global deaths, accounting for approximately 
17.3 million (95% uncertainty interval, 16.5–18.1 million) of the 54 million total mortalities, or 31.5% (95% 
uncertainty interval, 30.3%-32.9%) of all mortalities globally (Benjamin et al., 2017).  According to the Global 
Status Report on Non-Communicable Diseases, 2014, CVDs accounted for 11.4 million (48%) of the 23.6 million 
deaths reported for older populations.   
A large percentage of the global disease burden is directly from risk factors such as alcohol consumption, obesity, 
dietary factors and smoking or through other events such as increased blood glucose and cholesterol levels or high 
blood pressure (Ezzati et al., 2002, Lim et al., 2013). If the major risk factors for NCDs were eliminated, 
approximately three-quarters of the cases of heart disease, stroke and type 2 diabetes would be prevented; and 40% 
of cancers would be prevented (World Health Organisation Report, 2015). 
The prevalence of CVDs (comprising of cases of Coronary Heart Disease (CHD), Heart Failure (HF), stroke, and 
hypertension) in adults aged 20 years and older increases with age in both males and females (Benjamin et al., 2017, 
Benjamin et al., 2019;). There is evidence that CVDs, in approximately 70% of adults between the ages of 60 and 
79 years would present itself as either CHD, HF, stroke, or hypertension (Benjamin et al., 2017).  
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Despite the increase in the prevalence of CVDs the life expectancy in high income and some middle-income 
countries has increased due to reduced mortality rates in individuals aged 70 years and older (Sherlock et al., 2016; 
Kontis et al., 2017).  Sub-Saharan African countries in the African region are going through numerous stages of 
advancement related to social, economic, environmental and structural adjustments. Furthermore, as life 
expectancies increase due to economic advancement, the prevalence of CVDs is rising, producing a new burden on 
already struggling health systems (Chikafu et al., 2019, Hamid et al., 2019). Men and women in low and middle-
income countries have the highest risk of mortality as a result of NCDs (Figure 2). According to Di Cesare et al., 
2013, CVDs account for the highest proportions of deaths in both men and women from Central and eastern Europe 
and central Asia, followed by the Middle East and north Africa. Stratified by gender, a larger proportion of deaths 
have been reported for men when compared to women for the low-and middle-income countries as well as high 




Figure 2 illustrates the worldwide age-standardised death rate by region showing that death rates for most 
NCDs are lower in high-income countries than in low-income and middle-income countries (Di Cesare et al, 
2013).   
 
Sub-Saharan Africa (SSA) is experiencing an epidemic of CVDs on an unconceivable degree (Cappuccio et al., 
2016). Frailty and death caused by CVDs and the conventional risk factors, including hypertension, obesity, diabetes 
mellitus, and dyslipidemia, persist to increase in several SSA countries (Cappuccio et al., 2016, Amegah, 2018,). In 
2013, a projection of 1 million mortalities were due to CVDs in SSA, comprising 5.5% CVD-related mortalities 
worldwide and 11.3% of all mortalities in Africa. Between 1990 and 2013, SSA continued to be the only 
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geographical region of the world where CVD-correlated mortalities increased (Amegah, 2018). The high mortality 
rates in Africa due to ischemic heart disease appear to be related to the high prevalence of hypertension, 
hyperglycemia, and hypercholesterolemia (Fonseca et al., 2016). 
 
2.3 ROLE OF INFLAMMATION IN CORONARY HEART DISEASE (CHD)  
Inflammation is essential to the induction and advancement of atherothrombosis leading to CVD events (Yousuf et 
al., 2013). According to Luan et al., 2018, the response to inflammation is pivotal in most stages of atherosclerosis.   
Figure 3 illustrates the role of CRP in the pathogenesis of CVDs. Among other proatherogenic effects, CRP 
upregulates adhesion molecules such as intercellular adhesion molecule-1 [ICAM-1)] Vascular cell adhesion 
molecule 1(VCAM-1), and E-selectin. The upregulation of adhesion molecules occurs through the up-regulation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) which facilitates leukocyte transmigration 
by stimulating the release of Monocyte chemoattractant protein-1MCP-1 (Osman et al., 2006). CRP also upregulates 
angiotensin type-1 receptor (AT-1) in vascular smooth (ROS) construction (Verma et al., 2002). In addition, CRP 
inhibits bone marrow derived endothelial progenitor cell survival and differentiation, impairing maintenance of 
vascular integrity (Figure 3) (Luan et. al, 2018). This occurs at the very beginning with the recruitment of circulating 
leucocytes to the arterial wall until the unstable plaques become ruptured leading to the clinical manifestation of the 
actual disease. There is evidence that cardiovascular circumstances are connected to inflammation (Cardoso et al., 
2017). Similarly, inflammation plays a vital role in the pathogenesis of atherosclerosis from the formation of the 
atheriosclerotic lesion caused by lipid deposition to the rupture of fat plaques (Cardoso et al., 2017). This eventually 
leads to the occurrence of acute cardiovascular events (Habib et al., 2013). Evidence suggests that the atherosclerotic 
process is characterized by a low-grade inflammation altering the endothelium of the coronary arteries and is 
associated with increased levels of markers of inflammation (Moore et al., 2011).  
 
To improve global cardiovascular risk prediction, considerable interest has focused on the fact that CRP is not only 
an excellent biomarker of inflammation, but it is also a direct participant in atherogenesis (Velissaris et al., 2017). 
Many studies have demonstrated that increased CRP concentrations are associated with an increased risk of 
Myocardial Infarction (MI), stroke, peripheral arterial disease, and sudden cardiac death (Shrivastava et al., 2015).   
CHD is the leading cause of death and disability in developed nations and is increasing rapidly in the developing 
world (Moore et al., 2011). CVDs are the leading cause of mortality worldwide with CHD as the main cause of 
death in patients with heart conditions followed by stroke, rheumatic heart disease and MI (Sekhri et al., 2014). 
Almost half of all events associated with CHD are reported to occur in apparently healthy individuals who have few 
or none of the traditional risk factors, including dyslipidaemia. As a result, attention has increasingly turned to the 
role of other factors, such as inflammation, in the development of atherosclerosis and CHD (Shi et al., 2016). 
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Figure 3: Potential mechanism underlying the role of CRP in the pathogenesis of CVDs (Luan et. al, 2018).   
Abbreviations: DIC, disseminated intravascular coagulation; LDL, low-density lipoprotein; CVD, cardiovascular 
diseases; TG, triglyceride; MCP-1, monocyte chemoattractant protein 1; ICAM-1, intercellular adhesion molecule 
1; VCAM-1, vascular cell adhesion molecule 1; NO, nitric oxide; PI3K, phosphatidylinositol 3-kinase; ERK, 
extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; PAI-1, plasminogen activator 
inhibitor-1; TGF-β, transforming growth factor-β; CRP, C-reactive protein. 
 
2.4 C-REACTIVE PROTEIN (CRP) – HISTORIC PERSPECTIVES 
CRP was initially identified in 1930 by William Tillet and Thomas Francis at the Rockefeller Institute for Medical 
Research, in New York (Ridker, 2009, Shrivastava et al., 2015). Whilst studying the blood samples of patients 
suffering from acute Streptococcus pneumonia infection, it was discovered that serum samples from these patients 
produced a precipitin with an extract from the streptococcal bacterium. Initially, this extract was given the name, 
Fraction C, which was later confirmed to be a polysaccharide. As a result of its reactivity with the C polysaccharide 
of the Streptococcus cell wall, the ‘substance’ in the sera was named CRP (Shrivastava et al., 2015, Sproston et al., 
2018). After 100 years, the research team involving Oswald Avery and Maclyn McCarty highlighted that CRP was 
found to be in high levels in serum of patients suffering from a spectrum of inflammatory stimuli, including 
myocarditis and the inflammation associated with rheumatic fever (Ridker, 2003).  
 
CRP spreads at low quantities in healthy individuals, its concentrations expand significantly in reaction to infections, 
tissue injury and inflammation (Boncler et al., 2019). The role of CRP as a marker, specifically for CHD has been 
studied comprehensively (Biasucci et al., 2000; Sakkinen et al., 2002). CRP has been classified as a strong, 
independent risk factor for CHD by numerous major prospective clinical case-control studies (Biasucci et al., 2000; 
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Sakkinen et al., 2002). These studies concluded that CRP is an independent predictor of adverse cardiac events. The 
advance of high-sensitivity CRP (hs-CRP) assays has been beneficial to studying its role in forecasting initial 
cardiovascular events (Lubrano et al., 2015). 
 
2.5 C-REACTIVE PROTEIN AS A BIO-MARKER IN CARDIOVASCULAR DISEASES 
CRP is a member of the pentraxin superfamily that is extensively recognized as an indicator of inflammatory 
outcomes and cardiovascular probability in humans (McFadyen et al., 2018). Pentraxins are a superfamily of fluid 
phase pattern recognition molecules conserved in evolution and characterized by a cyclic multimeric structure. C 
reactive protein (CRP) and serum amyloid P component (SAP) constitute the short pentraxin arm of the superfamily 
(Bottazzi et al., 2016). Distinctive characteristics of CRP are its binding specificities and its site of synthesis which 
places it in a new super family of proteins (Bottazzi et al., 2016). Compared to other markers of inflammation, CRP 
levels are stable over long periods, have no diurnal changes, can be measured using high-sensitivity assays and have 
displayed good specificity with regards to predicting the risk of CHD (Burazor, 2004). CRP is an acute phase protein 
that is synthesized by hepatocytes in response to pro-inflammatory cytokines and interleukin-6(IL-6). CRP is also 
considered to be a predictor for the occurrence and progression of CVDs (Lee et al., 2014).  CRP is considered to 
be both a marker and a mediator of atherosclerosis and CHD (Sproston et al., 2018). CRP levels have been 
associated with prognosis in patients with different conditions such as atherosclerotic disease, congestive heart 
failure, atrial fibrillation, myocarditis, aortic valve disease, and heart transplantation. This link proves that CRP is 
actively involved in the pathophysiology process of CVDs (Osman et al., 2006).  
 
There is mounting evidence that inflammation is directly associated to atherosclerotic disease at all phases, from 
silent advancement to clinical expressions (Osman et al., 2006). There is epidemiologic data which suggests that 
intermediaries of inflammation, particularly hs-CRP, envisage cardiovascular threats autonomously of “traditional” 
risk factors (Osman et al., 2006). Figure 4 provides a clear description of the role that CRP plays as cardiovascular 




















Figure 4: Pathophysiological role of C-Reactive Protein in atherosclerosis, NO, Nitric Oxide, PAI-1, 
Plasminogen activator Inhibitor -1, LDL -Low-density Lipoprotein: Adapted from Ridker et al., 2003.  
 
CRP attaches itself to the phosphocholine of oxidized low-density lipoprotein (LDL), it also improves LDL uptake 
into macrophages and enhances the capacity of macrophages to create foam cells (Ridker et al., 2003). CRP impedes 
endothelial nitric oxide synthase expression in endothelial cells. Nitric oxide has its own important anti-atherogenic 
effects, including decreased platelet accumulation, vasoconstriction, and smooth muscle cell proliferation. It also 
improves plasminogen activator inhibitor-1 expression and action. CRP triggers macrophages to secrete tissue 
factor, a powerful procoagulant. CRP also upregulates the expression of adhesion molecules in endothelial cells 
that will bring together monocytes to the site of injury. High levels of CRP mRNA have been exhibited to appear 
in atherosclerotic plaques (Figure 4). 
 
2.6 BIOLOGICAL FUNCTIONS OF C-REACTIVE PROTEIN  
The role of CRP in host resistance has been considered to be mainly due to its capability to attach to phosphocholine 
(PC), stimulate the classical complement cascade, and improve phagocytosis (Simons et al., 2014). The ligand 
binding physical characteristics of CRP are also essential in realizing its role in inflammation (Simons et al., 2014). 
In addition to the recognition of microbial antigens, CRP reacts with cells at the sites of tissue injury (Luan et al., 
2018). Similarly, to serum amyloid P component (SAP), CRP attaches to nuclear antigens, injured membranes and 
apoptotic cells, and participates in the clearance of damaged or apoptotic cells, as well as the material distributed 
from these ravaged cells (Boncler et al., 2019).  
During infection, inflammation or injury, CRP inhibits endothelial nitric oxide production and contributes to plaque 
instability by increasing the expression of endothelial cell adhesion molecules; by promoting monocyte recruitment 
into the atheromatous plaque and by enzymatically binding to modified LDL. CRP also plays a fundamental role in 
thrombosis (Badimon et al., 2018). Evidence indicates that CRP contributes to CVDs by several processes, however, 
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more research in this area is still required (Badimon et al., 2018). The processes are represented in Figure 5 and 
include endothelial dysfunction, atherosclerotic plaque development and advancement. CRP down-regulates the 
transcription of endothelial nitric oxide synthase (eNOS) in endothelial cells (EC); which destabilizes eNOS mRNA, 
leading to a reduction in NO release (Osman et al., 2006). This inhibition of NO production enhances endothelial 















Figure 5:  Representation of CRP-mediated effects on atherosclerosis and CHD (Shrivastava et al., 2015).   
 
CRP may also stimulate the construction of endothelin-1(ET-1), a vigorous endogenous vasoconstrictor and 
intermediary of endothelial dysfunction, leukocyte and platelet stimulation and cellular proliferation (Miyauchi and 
Masaki, 1999). Finally, CRP stimulates the production of IL-6 in the vasculature (Yudkin et al., 2000). This finding 
is particularly important since IL- 6 is involved in a positive feedback loop to stimulate CRP production by the liver 
(Verma et al., 2002). CRP is different to other immunoglobulin molecules; however, it also has some similar 
functional properties with other immunoglobulins. These similarities include the capability to encourage 
agglutination, activation of the classical complement pathway, bacterial capsular swelling, phagocytosis and 
precipitation of poly cationic and poly anionic compounds. By analogy with antibodies, it is therefore possible that 
CRP might contribute both to host defence against infection and enhancement of inflammatory tissue damage (Luan 
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2.7 ATHEROSCLEROSIS, CHRONIC INFLAMMATION, AND C-REACTIVE PROTEIN 
Atherosclerosis leads to ischemic stroke; however, modification of lifestyle and control of cardiovascular risk 
factors can prevent it (Tsivgoulis et al., 2018). The mechanism of inflammation plays a crucial role in all levels of 
atherosclerosis, from the recruitment of circulating leukocytes to the arterial wall, to the rupture of unstable plaques, 
which leads to clinical manifestations of the disease (Burazor., 2004). 
Chronic inflammation is a well-established background process in many age-related diseases (Rea et al., 2018). 
Recent studies by Su et al., 2013 and Salazar et al., 2014 investigated the use of various inflammatory biomarkers 
such as CRP, IL-6, and IL-1 as predictors of physical and cognitive performance amongst the aged. These 
prospective cohort studies have shown that elevated CRP levels are associated with increased CHD risk in both 
genders, across a wide age range, and in primary as well as secondary prevention settings (Velissaris et al., 2017). 
These findings have been consistent in different populations with diverse ethnic backgrounds and in diverse clinical 
settings, and they have predicted risk for a variety of cardiovascular outcomes, including incident stroke, sudden 
cardiac death, peripheral artery disease and incident diabetes as well as new onset hypertension (Burazor, 2004). 
CRP levels have also been shown to predict risk of both recurrent ischemia and death among those with stable and 
unstable angina, those undergoing percutaneous angioplasty, and those presenting to emergency rooms with acute 
coronary syndrome (ACS) (Martín-Timón et al., 2014).   
Research has revealed that CRP is manufactured by human artery smooth muscle cells of atherosclerotic lesions in 
reaction to inflammatory cytokines thereby advocating the advancement of cardiovascular difficulties (Pfützner et 
al., 2010). CRP may be associated at all levels by directly impacting processes such as complement activation, 
apoptosis, vascular cell activation, monocyte recruitment, lipid accumulation and thrombosis (Luan et al., 2018). 
This occurs through the complement pathway which consists of 35 plasma or membrane proteins which play a vital 
role in immunity and acts as a defence mechanism against either, inflammation, infection or injury (Li et al., 2007). 
The complement pathway has different components that become activated in three different pathways to trigger a 
cascade of proteins, which are used to bind microbial surfaces, leading to the activation of phagocytosis or cell lysis 
(Speidl et al., 2011) (Figure 6) 
Complement (a major human immune system defence mechanism) together with CRP form part of substances found 
in the atherosclerotic lesion, explicitly in the vascular intima, where it co-localizes with monocytes, monocyte-
derived macrophages and lipoproteins (Moore et al., 2011; Sproston et al., 2018) (Figure 6) 
 
 























Figure 6: Effects of complement activation in atherosclerosis (Speidl et al., 2011) 
 
The Diagram (Figure 6) illustrates the of effects of complement activation in atherosclerosis in which sub-lytic 
concentrations of the terminal complement complex induce endothelial and smooth muscle cell proliferation and 
the release of growth factors. It increases the expression of adhesion molecules on endothelial cells and the release 
of chemokines and tissue factor from endothelial and smooth muscle cells. The anaphylatoxins C3a and C5a activate 
and trigger oxidative burst in macrophages and neutrophils and are also regarded as chemoatractants for eosinophils, 
mast cells, monocytes, and B- as well T-lymphocytes. C5a induces tissue factor, plasminogen activator inhibitor-1 
and matrix metalloproteinases in macrophages but acts also on mast cells, endothelial cells and smooth muscle cells. 
Opsonins promote the clearance of atherosclerotic plaques from apoptotic cells, debris and immune complexes. 
C1q, C3b and C4b bind to apoptotic cells and induce their phagocytosis by macrophages via complement receptors. 
PAI-1 (plasminogen activator inhibitor-1); MMPs (matrix metalloproteinases); SMCs (smooth muscle cells) (Speidl 
et al., 2011). 
 
Page 28 of 105  
  
 
2.8 CLINICAL IMPORTANCE OF CRP  
CRP is useful as a clinical marker for the following reasons: commercially robust assays are available for measuring 
its levels; the protein is stable in serum or plasma with very marginal fluctuations; and assays for detection are 
simple and cost effective (Shrivastava et al., 2015). In addition, assay outputs are similar when testing either fresh, 
stored, or frozen serum or plasma samples. CRP circulating levels has been found to be within similar ranges to 
other inflammatory markers (Brindle et al., 2010, Doumatey et al., 2014,). Additionally, the intrinsic biological 
properties of CRP as an acute-phase reactant are especially favorable for its use as a sensitive quantitative systemic 
measure of the acute-phase response (Shrivastava et al., 2015). CRP has unique properties and can provide closer 
predictions when compared to other markers (Salazar et al., 2014). Studies suggest that elevated hs-CRP levels can 
predict poor cardiovascular prognosis over and above to assessing future risk in asymptomatic individuals (Fonseca 
et al., 2016).  
 
Furthermore, CRP levels are useful in motivating patients to modify their lifestyles more aggressively (Mora et al., 
2009). The CRP concentration is therefore a very useful nonspecific biochemical marker of inflammation. 
(Shrivastava et al., 2015). Determination of CRP levels is important for the following reasons: (a) screening for 
organic disease (Organic disease is the term used to describe any health condition in which there is an observable 
and measurable disease process, such as inflammation or tissue damage), (b) monitoring responses to treatment 
(serial measurements reflects activity and response to treatment and can be used for monitoring), and (c) detection 
of recurrent infection in immuno-compromised individuals (Shrivastava et al., 2015).   
 
2.9 RATIONALE FOR CURRENT STUDY  
Cardiovascular diseases (CVDs) remain a key public health challenge globally (Boateng et al., 2018). POC testing 
has the ability to provide rapid results thus improving patient management (Stone et al., 2007). Recent studies 
have shown a number of settings where POC technology is equivalent to gold standard centralized laboratory 
methods in terms of diagnosis and patient care (Urdea et al., 2006).  
Abbai et al., 2018, supported the use of the Alere Afinion™ AS100 Analyser as a POC test to quantify HbA1C, 
triglycerides and HDL-C in a South African setting.  Presently there is lack of data on POC technology for the 
measurement of CRP levels, especially in older persons. This study will be the first to evaluate the diagnostic 
performance of the Alere Afinion™ AS100 analyser (Alere, South Africa) when compared to the ABX Pentra 400 
analyser (reference test) for measuring the levels of CRP in an older South African population. If the POC test is 
found to be comparable to the reference test, this will have a positive impact in terms of screening and linkage to 
care in resource limited settings. In addition, the data generated from this study will provide insights regarding the 
prevalence of CVDs in the study population as well as to identify risk factors associated with elevated CRP levels 
which will facilitate better patient management.    
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2.10 STUDY AIM AND OBJECTIVES  
2.10.1 AIM   
To evaluate the diagnostic performance of the Alere Afinion™ AS100 Analyser when compared to the ABX Pentra 
400 for the determination of C-reactive protein levels in a population of older men and women from KwaZulu-Natal 
Province, South Africa. 
  
2.10.2 OBJECTIVES OF THE ACCOMPLISHED STUDY  
- To compare the sensitivity and specificity of the Alere Afinion™ AS100 analyser to the reference test, 
ABX Pentra 400 for the measurement of C-reactive protein levels  
- To determine the prevalence of risk factors associated with cardiovascular diseases in the studied population  
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                                          CHAPTER THREE: METHODS  
 
3.1 STUDY DESIGN AND POPULATION   
This study was a retrospective analysis utilizing stored serum samples obtained from a cross-sectional study, Sexual 
Health, HIV infection and comorbidity with non-communicable diseases among Older Persons (SHIOP). The 
SHIOP study was a cross-sectional study conducted from February to April 2016. Participants in the SHIOP study 
were aged 50 years and older, not cognitively impaired, based on observation by the interviewer and willing to 
provide written informed consent. All participants provided information on their sexual behaviour, health status and 
were screened for CVD biomarkers. Participants were recruited using a convenient sampling approach from two 
areas within the eThekwini district, i.e. Chatsworth (urban area) and Botha’s Hill (semi-rural). The primary aim of 
SHIOP was to describe sexuality, sexual health, HIV and comorbidity with chronic non-communicable diseases in 
adults aged ≥50 years in a setting of high HIV prevalence. The study enrolled n=435 participants across the two 
study areas. All enrolled participants provided written consent after being provided with information about the study 
and had to demonstrate adequate understanding of the information before signing the consent form. In cases where 
the participant was illiterate, they could invite a neutral person who was not a member of the study team or employee 
of the research organisation to witness the informed consent process. Where a participant was not able to write and 
sign the consent form, they were provided with ink pads for them to mark the consent form with their thumb print. 
Further details on the SHIOP can be found elsewhere [Abbai et al., 2018 & Nyirenda et al., 2018].  
  
3.2 STUDY PROCEDURES   
All enrolled participants were tested for Human Immunodeficiency Virus (HIV) and Sexually Transmitted 
Infections (STIs) in the SHIOP study.  Additional medical history information was collected via self-reports as 
well as objectively measured on chronic morbidities (diabetes, hypertension, renal, and cholesterol). In this study, 
using glycated haemoglobin (HbA1c) levels, participants were categorised as diabetic (HbA1c>6.5%), pre-
diabetic (HbA1c 5.7%-6.4%) or normal (HbA1c<5.7%). Spot-collected albumin readings were used to determine 
renal or chronic kidney disease (CKD). As per Kidney Disease Improving Global Outcomes (KDIGO) guidelines 
participants were categorised as at severely high risk of renal disease (albuminuria >300mg/g), at moderate risk 
(albuminuria 30-300mg/g) and normal or mild risk (albuminuria <30mg/g) (Tongma et al., 2013). For 
hypertension, three readings of blood pressure (BP) were taken using a fully automatic Healthease digital arm BP 
instrument. Participants were in a sitting position with a one-minute rest between each reading. A mean of the 
three readings was calculated with participants categorised as hypertensive if their systolic blood pressure was 
≥140mm Hg or diastolic blood pressure ≥90 mm Hg, based on the World Health Organization’s (WHO) 
recommended hypertension cut points.  
Participants who tested positive for STIs (Neisseria gonorrhoeae, Chlamydia trachomatis and syphilis), HIV and/or 
had high HbA1c, albumin, cholesterol or hypertension readings as per cut-points above were referred to local clinics 
for care. In addition, all participants underwent physical examinations whereby measurements for blood pressure, 
weight and height were taken. The data obtained from the physical assessments were used to determine the 
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proportion of participants with diabetes, chronic kidney disease and hypertension, and the risk factors associated 
with high CRP levels in the studied population.   
  
3.3 SAMPLE COLLECTION AND PROCESSING  
Enrolled participants provided venous blood samples for laboratory testing. Blood collection was performed 
according to Good Clinical Laboratory Practices (GCLP) by a trained nurse where whole blood was drawn 
aseptically into a serum separator gel (SST) tube and an ethylenediamine tetra-acetic acid (EDTA) tube.  
The onsite laboratory at the clinical research site housed all the equipment required to process the samples such as 
separation of the serum and plasma fractions. The onsite Laboratory was also responsible to process all samples as 
per laboratory procedures. SST specimens were centrifuged at 3000 rpm for 10 minutes, serum was then separated 
into an aliquot tube for testing in the central laboratory. Certain tests were performed at the onsite laboratory by 
qualified, trained Medical Technologists. The remainder of the aliquoted serum samples were shipped at 2-8⁰C to 
the central laboratory for testing and long-term storage. Only the samples of participants who consented to long 
term storage were stored.  
The serum fraction was used for determining the CRP levels. In order to preserve sample integrity, the serum and 
plasma samples were stored at -80 ⁰C and -20 ⁰C for further testing. The samples were stored for approximately 1.5 
years (February 2016- August 2017) before being retrieved for testing in this study. 
  
3.4 ETHICAL APPROVAL  
This retrospective study was approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal (BE074/17), whereas the parent SHIOP study was approved by the South African Medical 
Council Ethics Committee (ECO30-9-2015).  
  
3.5 SAMPLE RETRIEVAL AND TESTING   
Only stored serum samples from participants who consented to storage and future testing during the SHIOP study 
were utilized in this study. Of the 435 participants enrolled in the parent study, only n=183 participants consented 
to storage and future testing, hence only 183 samples were available for testing for this study. Samples were 
retrieved from the Biorepository freezers, allowed to thaw and tested in batches of n=50, to allow for complete 
testing on both the Alere Afinion™ AS100 and ABX Pentra 400 analyzers.   
  
3.6 LABORATORY TESTING - DETERMINATION OF CRP LEVELS   
Samples were tested on both the ABX Pentra 400 and the Alere Afinion™ AS100 for CRP levels. The CRP 
levels were measured by commercially available turbidimetric and immunochemical methods, respectively.  
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3.7 ALERE AFINION™ AS100 PRINCIPLE  
The principle of this assay is based on a solid phase immunochemical test assay in which the sample is 
automatically diluted with a liquid (which is the component of the CRP reagent within the cartridge) that also 
lyses the red cells. The Alere Afinion™ CRP Test Cartridge contains all the reagents necessary for measuring the 
CRP concentration in serum or plasma. Figure 7 is an illustration of the testing procedure in which the sample 
mixture was passed through a membrane coated with anti-CRP antibodies; the CRP in the sample was 
concentrated onto this membrane. A solution containing anti-CRP antibodies conjugated with ultra-small gold 
particles was passed through the membrane. The gold-antibody conjugate binded to the immobilized CRP on the 
membrane, which turned reddish brown. Excess gold-antibody conjugate was removed by a washing solution. The 
Alere Afinion™ AS100 Analyser measured the colour intensity of the membrane, and this was proportional to the 
amount of CRP in the sample. The CRP concentration was displayed on the Analyser screen (Figure 8) (Afinion™ 
CRP manual [pamphlet]. Oslo, Norway: Axis Shield PoC AS; 2010). The measurement range used was 5 to 160 



























Figure 8: Analyser touch screen and Cartridge chamber.1-Text message, 2- Touch buttons, 3- The lid in open 
position, 4- The cartridge chamber with a test cartridge  
 
The main components of the Test Cartridge were the sampling device and the reagent container. The Test Cartridge 
had a handle, a barcode label with lot-specific information and an area for sample ID (Figure 9). Participant ID was 
recorded on the space provided on the cartridge. Figure 10 provides a quick guide of the test procedure, from sample 
testing to results generation and cartridge discard after completion of the test procedure (Afinion™ CRP manual 
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Figure 10: Illustration of the test procedure from the quick guide  
  
3.8 ALERE AFINION™ AS100 QUALITY CONTROL  
Quality control testing was performed to confirm that the Alere Afinion™ AS100 Analyser system was working 
properly and providing reliable results. All procedures were performed as per manufacturer’s instructions. No 
problems were experienced with the Controls. The measured values of the CRP were always within acceptable 
limits (5-160 mg/L) as stated in the CRP control Package inserts. Controls were stored in the fridge (2- 8°C) as per 
manufacturer’s instructions. The control material was used without waiting for it to reach equilibration to room 
temperature, as indicated on the reagent package insert. The control was mixed well by inverting the vial 8-10 
times before the sample was added. Only Afinion™ CRP Controls from Axis-Shield were used as recommended 
by the manufacturer. The Afinion™ CRP Control kit contained assayed human serum controls at two 
concentration levels of CRP. The CRP Control kit contained: Liquid human serum with purified CRP at two 
concentration levels; Afinion™ CRP Control C I and Afinion™ CRP Control C II. These were tested prior to 
sample testing.   
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The quality control printout from the Afinion™ AS100 Analyser could not be included in this thesis as the thermal 
paper on which the results were recorded had faded away. However, the laboratory’s internal quality control log 
has been added as an appendix to show how internal quality control was recorded (Appendix 12).  
 
3.9 ALERE AFINION™ AS100 ANALYSER SAMPLE TESTING   
All testing was conducted in accordance with the manufacturer’s instructions. The analyser was placed away from 
the sunlight. As part of routine analyser maintenance, the analyser would first start by performing its self-test upon 
being switched on. Samples were tested after the analyser had completed the self-test by indicating with a green 
light that it is was ready for use. Unlike the control material, upon removal from storage, the CRP  
Test Cartridge could be allowed to reach a temperature of 15-30°C before use, as indicated by manufacturer’s 
instructions. The cartridge was then labeled with the participant study number. The CRP levels were measured using 
1.5 μL of serum. The assay time was ~4 minutes and controls with specific target ranges were included in each 
assay run.  Based on available data, diagnostic cut-off for high sensitivity assays for CRP levels is 1.1mg/L-3mg/L 
for low to moderate risk and 3mg/L and above correspond to high-risk groups for future cardiovascular events 
(Ridker, 2003, Pearson et al., 2003). However, due to the Afinion™ AS100 Analysers detection limit of 5mg/L, 
5mg/L was used as the diagnostic cut-off in this study. 
 
3.10 THE REFERENCE METHOD – ABX PENTRA 400 CRP TEST  
 In order to evaluate the performance of the Alere Afinion™ AS100, the ABX Pentra 400 analyser was used as the 
reference test in this study. All assays were performed according to the manufacturer’s instructions. The diagnostic 
cut-off for CRP used was ≥5 mg/L. This range was used to compare and categorise participants as normal v. 
abnormal. The ABX Pentra 400 is a compact Clinical Chemistry benchtop analyzer (Figure 11, A). Its great 
autonomy with continuous loading provides enhanced productivity in a user-friendly environment. The ABX Pentra 
400 uses high-quality analytical technology with a single use reaction cuvette to perform the most effective tests 
with high stability and quality results. It has a high-performance mixer design for optimal mixing in minimum time 
without risk of cross contamination. It has the optimum test sequence setting program with an incompatibility 
function.  
   
 
                    








3.11 THE PRINCIPLE OF THE ABX PENTRA 400 CRP TEST  
The gold standard method is a latex-enhanced immuno-turbidimetric assay developed to accurately measure CRP 
levels in serum and plasma samples. This assay involves the immune-turbidimetry with 3 stages. During the first 
stage, blood cells are lysed by Reagent 1. During the second stage of the assay, Reagent 2 which inhibits 
interference is added and the last stage involves the addition of the Reagent 3 which contains anti-CRP antibodies 
bound to latex beads. When an antigen-antibody reaction occurs between CRP in a sample and anti CRP antibody 
which has been sensitized to latex particles, agglutination results. This agglutination is detected as an absorbance 
change, with the magnitude of the change being proportional to the quantity of CRP in the sample.   
The actual concentration is then determined by interpolation from a calibration curve prepared from calibrators of 
known concentration. Absorbance is then measured at 850nm, and the absorbance is proportional to the CRP 
concentration of the sample.  All this is automatically performed as the sample is analysed by the ABX Pentra 400 
analyser (ABX Pentra 400 Package insert). Approximately 4.0 μL of serum is required for this assay. The minimum 
interpretation limit (MIL) is evaluated using multiple determination of low concentration specimen and equals 3.00 
mg/L with a Lower limit of detection (LLOD) of 1.00 mg/L. CRP reagent, with associated calibrators and controls, 
were used. The ABX Pentra Immuno I Control L/H was used as a quality control to monitor accuracy and precision 
for CRP.  Measurements of CRP ranged from 0.1 mg/L to 43.8 mg/L, with a median of 0.5 mg/L.  
 
3.12 ABX PENTRA 400 REAGENTS  
The ABX Pentra CRP (Cartridge Pack: CP) is ready-to-use. In order to maintain the integrity and stability of the 
reagents, during the testing procedure, reagents cassettes were left in the ABX Pentra 400 refrigerated tray after 
analysis. Care was taken to ensure reagent caps were not interchanged with other reagent cassettes. Since only183 
samples were tested, only one lot number of CRP reagent was used, so there was no risk of interchanging or mixing 
of different lot numbers. ABX Pentra CRP CP was used according to the package insert provided with the reagent 
by the supplier. The reagents used in the measurement of the CRP CP included: Reagent 1 Buffer solution which is 
the Glycine buffer solution and Reagent 2: Latex suspension which is 0.20% w/v suspension of latex particles 
sensitized with anti-CRP antibodies (rabbit). Both caps of the cassette were placed in the refrigerated ABX Pentra 
400 Reagent compartment as per manufacturer’s instructions. Reagents were inspected for foam and bubbles, if 
present this was removed by using a plastic Pasteur pipette.   
 
3.13 ABX PENTRA 400 CALIBRATION  
Calibration was not performed as the manufacturer advises that this be done only after a lot number change. Since 
only one lot number was used, there was no need to perform a calibration as the internal quality Control was checked 
and verified to be acceptable prior to testing the samples.  
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3.14 ABX PENTRA 400 INTERNAL QUALITY CONTROL    
It is fundamental to ensure Internal Quality Control is optimised in order to ensure that reliable and valid results are 
produced for proper patient diagnosis, management and care. In order to ensure valid analytical runs on the reference 
method, ABX Pentra Immuno I Control L/H, Ref. A11A01621 ABX Pentra Low CRP Control, Ref. A11A01731 
(low and high controls) were used. Both low and high controls were tested daily prior to testing the samples. Internal 
Quality Control results were reviewed and checked against expected values.   
Only when quality control was within the acceptable range, then samples were tested. Internal Quality Control was 
performed as per the manufacturer’s instructions, ABX Pentra Immuno I Control L/H was tested daily prior to 
sample processing in order to check the status of the analyser, to verify that it is in good working condition and that 
it will produce reliable and good quality results. The results were within the range of the defined confidence limits. 
Calibration was not performed as the testing of the sample occurred within a month. The manufacturer claims that 
the CRP reference range for adults (20-60 years) is < 5mg/L.  
 
3.15 THE FREQUENCY OF THE PENTRA 400 INTERNAL QUALITY CONTROL   
Each control was assayed daily as per manufacturer’s instructions. The frequency of controls and the confidence 
intervals were corresponding to laboratory guidelines and country-specific directives. Samples were tested after the 
Internal Control results were reviewed and within the range of the defined confidence limits. The package inserts 
of the ABX Pentra 400 CRP as well as the ABX Pentra 400 instructional manual were followed and used as the 
Standard Operating Procedures. 
  
3.16 ABX PENTRA 400 TESTING PROCEDURE  
All maintenance procedures were completed, internal quality controls were run as per manufacturer’s instructions. 
The CRP Reagents came as a kit that it is ready to use. No preparation/ reconstitution of the reagents was required.  
During the installation of reagent cartridge, the CRP reagent door which is located on the right-hand side of the 
ABX Pentra 400 analyser was opened. The CRP Reagent kit consisted of R1, R2 and R3, these were all removed 
from the refrigerator and added to the analyser. The door was closed and verified that it was properly  
closed into its locking device as per manufacturer’s instruction. The new CRP sensitivity factors were entered on 
the analyser by following the instruction manual. Single use cuvettes as depicted on Figure 12 were added on the 
analyser. These cuvettes ensured that there was no risk of cross-contamination.   
 




Figure 12: ABX Pentra 400 sample reaction cuvettes 
   
3.17 COMPARISON OF THE AFINION AS100 AND THE ABX PENTRA 400  
3.17.1 WORKING BENCH SPACE  
The Pentra 400 system requires approximately 150cm width of bench, which includes enough space for the analyser, 
printer, keyboard and to access the cuvette carousel for troubleshooting. It also requires a 91cm depth of bench 
(analyser 80cm deep plus 20cm clearance, 110 cm clearance above bench for the analyser with the lid raised, 70cm 
(width) x 60cm (depth) x 60cm (height) under the bench to house the cooling unit, the waste and water tanks, and 
22cm x 56cm x 22xm (height)for the optional UPS. The Afinion™ Analyser has dimensions of 17cm x 19cm x 
34cm therefore requiring much less bench space (Piggott et al., 2005). 
 
3.17.2 DESCRIPTION AND EASE OF USE  
The Pentra 400 system is compact although space is required under the bench for a cooling unit, water and waste 
bottles, and access to the back is required when changing the filter during maintenance. The analyser overhangs a 
60cm wide bench. The system software is generally easy to use but some of the icons are confusing at first and 
require extensive training for the users. Reagents are ready to use and easy to load onto the system, however, bubbles 
can be difficult to remove. The reagent carousel has a refrigerated section and an ambient temperature section and 
errors will occur if reagents are loaded into the wrong section; there is no facility to prevent this. User’s require 
extensive training in order to prevent errors (Piggott et al., 2005). The Afinion is simple and easy to use. The touch 
screen of the Analyzer provides a simple graphical user interface (GUI). Coloured icons are used for language-
independent touch buttons while the local language can be chosen for text messages. 
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The Afinion™ CRP analysis can be done on either the capillary or venous blood sample which takes just 
approximately 3minutes. A simple sampling procedure, easy touch screen user interface, no manual calibration, no 
chemistry handling or manual calculation of results makes the Afinion™ Analyser system suitable for both 
laboratory and non-laboratory users (Afinion™ CRP manual [pamphlet, 2010). 
To run an Afinion™ CRP test, there are no additional instruments required apart from the standard capillary or 
venous puncture equipment. Printer and barcode-scanner (for entering sample ID) can be connected, this is optional. 
The Test Cartridge is placed in the cartridge chamber and the analysis starts by closing the lid manually. Once 
loaded with a cartridge, the Afinion™ Analyzer represents a true walk-away system. After analysis the result is 
stored and displayed on the screen. When the result is accepted or transferred to a connected printer or data system, 
the lid opens automatically, and the used cartridge can be removed and discarded (Afinion™ CRP manual 
[pamphlet, 2010).  
 
3.17.3 MAINTENANCE  
The Pentra 400 system requires daily, weekly and monthly maintenance for the system to perform optimally. 
Scheduled maintenance procedures include: a start-up (beginning of the day) and shutdown (end of the day). The 
procedures are performed on daily basis, requiring approximately 10-15minutes for each process. These steps can 
only be performed by trained laboratory staff.  Whereas the Afinion™ Analyser requires cleaning and disinfecting 
the exterior of the analyser prior to use and cleaning and disinfecting of the cartridge chamber on a monthly basis 
(Piggott et al., 2005). 
 
3.17.4 CALIBRATION  
The Pentra 400 requires that calibration be performed for each new reagent cassette regardless of lot number 
change. The packaging of the CRP Reagents which contained the CRP reagent sensitivity factor needs to be 
retained for the sensitivity factors to be entered on the calibration menu so as to ensure that the result produced by 
the analyser was reliable (Piggott et al., 2005). While, the Afinion™ Analysers are calibrated against a reference 
system to ensure that all Analysers operate within identical tolerance limits during manufacturing. Test specific 
calibration data are established for each lot of test cartridges and then stored in the barcode label. When the 
cartridge is placed in the Afinion™Analyser, the integrated camera reads the barcode. The calibration data for the 
actual lot is transferred to the analyzer and used for calculating the results. Calibration by the operator is thus not 
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TABLE 1: Comparison between Afinion and ABX Pentra 400 systems, (NICE, 2016, Piggott et al., 2005) 
 Afinion Pentra 400 
Size:  13.4cm x 6.7cm x 7.4 cm 40” x 28” x 25” (W x L x H) 
Width=101cm, height=63cm, Depth=71cm 
External Cooling Unit: Width =29cm, 
height=40cm, depth=42cm 
Weight  4Kg 120kg + 35kg (Cooling system) 
Users Suitable for both laboratory and non-
laboratory users 
Needs trained laboratory personnel 
Sample volume/test 1.5 μL of serum 4.0 μL of serum 
Cost per test £3.50 (R67.34) (excluding VAT) Per test= £1.31=R25.19 (Excluding VAT) 
Reagents  All-in-one test cartridge ABX Pentra CRP CP is ready-to-use. 
Measuring range  8 - 200 mg/L (whole blood), 5 - 160 
mg/L (serum and plasma) 
0.10mg/L-160mg/L (serum and plasma) 
Reagent storage and 
stability 
The CRP test cartridge contains all 
reagents necessary for the 
measurement of C-reactive protein 
with 4 weeks room temperature 
stability 
Refrigerated (2-8°C) until the expiry 
date or at room temperature (15-25°C) 
stable for maximum 4 weeks  
Reagents in unopened cassettes are stable up to 
the expiry date on the label if stored at 2-10 °C 
and protected from light. 
Once opened, the reagent cassette placed in the 
refrigerated ABX 
Pentra 400 reagent compartment is stable for 64 
days 
Materials required 
but not provided 
None NaCl solution: 9 g/L, ABX Pentra Clean-Chem 
CP, Ref. A11A01755, 30ml 
Detection Limit 5-160mg/L 0.10-400mg/L 
Maintenance  Cleaning of cartridge chamber with a 
swab once a month 




Approximately 3minutes  Start-up procedure from downtime varies from 
10-15minutes 
Practical aspects of 
the assay 
Auto-self check with integrated error 
detection. Error codes possible due to 
small sample volume that may dry out 
after the 1min limit instructed in the 
package insert  
The sample probe has clot detection but no 
bubble detection. Operators must remove 
bubbles from samples before loading on the 








Figure 13:  Illustration of the Pentra 400 system (A), separate keyboard and printer (not shown). A floor-




3.18. DATA ANALYSIS  
  
3.18.1 DESCRIPTION OF VARIABLES   
The socio-demographic, behavioural, laboratory and clinical variables analysed in this study were collected during 
the main SHIOP study. This data was collected using an interview administered questionnaires (see attached 
appendix 11), clinical and laboratory report forms. The clinical data was obtained after physical examinations were 
performed such as weight and height measurements. The laboratory data was obtained from the various tests which 
were conducted by the main study technologists. The socio-demographic variables analysed in this study included 
age which was collected in single years. It was initially analysed as a continuous variable using means and medians 
with age range of participants from 50 to 94 years old. Age was then grouped into broad age groups of 50-59 years, 
60-69 years and 70+ years for further analyses. Participants were asked to self-identify with a population group and 
identified as one of three groups: African, Indian or White. The one participant who self-identified as white was 
excluded from further analyses since no statistical analysis could be performed with just one individual of this 
population group .  
Civil, traditional or religious forms of marriage were all recognised as marriages in this study. Participants therefore 
had to state their marital status as never been married, married, co-habiting, separated/divorced, or widowed. 
Regarding religion participants were asked to state their religion from specified options of Christian, Hindu, 
Muslim, Jewish, none (not belonging to any religious grouping) or to specify if any other. From participant 
responses religion was then categorised into Christian or Hindu in this analysis. Regarding education, participants 
were asked to report whether they had no formal education, had completed or not completed primary school, had 
completed or not completed secondary school, or attained tertiary level (post-matric college or university) education 
or don’t know. Due to the school sample sizes in the study, education level was recategorized as had no formal 
education, primary (combined completed and not completed), secondary (combined completed and not completed).  
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Other socio-demographic variables included in the study were employment (formal or informal) status (Yes/No); 
smoking (Never/Ever smoked); alcohol use (Never/Ever taken an alcoholic beverage); having an income source 
from self-employment, odd jobs, selling or trading, from formal employment wages; from government grants; from 
property rentals; from retirement fund; other sources or no income source. Income sources were later recategorized 
into government grants, other or none due to the small numbers in the initial categories. The other variable included 
in the descriptive factors of participants was HIV status based on results from the HIV testing conducted in the 
study. Participants were grouped into HIV positive or HIV negative categories.  
 
3.18.2 STATISTICAL ANALYSIS 
Data was analysed using correlation coefficients to assess agreement of CRP readings between the Alere AfinionTM 
AS100 instrument and the gold standard instrument, ABX Pentra 400. Data was further analyzed using the Bland-
Altman analysis method. The Bland-Altman method compared mean differences between the Alere AfinionTM 
AS100 instrument and standard laboratory method (mean bias). The 95% limits of agreement between the Alere 
AfinionTM AS100 and laboratory measurements were calculated. The Bland-Altman methods were appropriate for 
this analysis since there was no repeat measurements on each method per participant, i. e there were two sets of 
measurements for each participant (one for the Alere AfinionTM AS100 and for the ABX Pentra 400 method). This 
showed that the two sets of measurements were independent making this approach suitable for data analysis of this 
evaluation study. Graphical Bland-Altman plots and scatter plots were used to depict the study findings.   
 
Univariable and multi-variable linear regression analyses were used to analyse the data for factors associated with 
elevated CRP levels. The data are presented as odds ratios, which are exponents of the regression coefficients. The 
proportion of participants with elevated CRP in the studied population was based on the ABX Pentra 400 results as 
the gold standard. Regression analysis was used to identify risk factors associated with elevated CRP levels in the 
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CHAPTER FOUR  
  
4.1 RESULTS  
4.1.1 CHARACTERISTICS OF THE STUDY POPULATION   
The baseline characteristics of the study sample (n=183) are summarized in Table 2. The mean age of the study 
participants was 7.62 years (SD 8.15). Male participants were slightly older than female participants (61 v. 58 
years, p<0.05). Approximately 14.2% of study participants were above 70 years of age, and just over half of the 
participants were in the youngest age group 50-59 (50.3%) p=0.482. The study population consisted of 77/183 
(42.0%) Black South Africans and 106/183 (57.9%) Indians Approximately 24.6%(p=0.117) of study participants 
reported to have never been married, 30.6% were married, and 4.8% were cohabiting, 6.7 % were either separated 
or divorced and 33.1% were widowed.  
  
A large percentage (70.5%) (p=0.399) of the participants reported to be Christians, with 29.5% belonging to the 
Hindu religion. Only 12% (p=0.493) had never been to school, 44.8 % had primary school education, and 43.2% 
had secondary school education. For this analysis there were only 2 participants with tertiary education. These were 
combined with secondary, which was labelled as secondary or higher. Regarding economic activity, 6.6% (p=0.486) 
were employed, 88% were unemployed and 5.5% reported to have been retired. In this study we only looked at 
those who were unemployed at the time of the study. The questionnaire did not probe for whether they had been 
employed previously.  
 
With regards to smoking habits, 73.2% (p=0.506) reported to be non-smokers, that is, had never smoked in their 
lives. Just over a quarter, 26.8% had ever smoked, that is, they were currently smoking or previously smoked. The 
number of ex-smokers was very small. Further because of the long-term effects of smoking we anticipated the risk 
of developing cardiovascular conditions would be similar between ex-smokers and current smokers compared to 
never smoked. Hence the smokers were grouped with the ex-smokers for data analysis. A large proportion (80.9%) 
(p=0.235) never consumed alcohol in their lives, whereas 19.1% currently consumed or had previously been 
consuming alcohol. In terms of income generation, 71.0%(p=0.984) were receiving a government grant, 23.5% 
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4.1.1.1 CRP LEVELS IN THE STUDIED POPULATION 
Table 2 illustrates CRP levels and risk factors associated with elevated CRP levels in the studied population. In the 
gender group that had elevated CRP levels, females constituted the highest proportion (70.8%) and only 29.2% of 
the group were males. However, with regards to the group that had normal CRP levels, the larger proportion (54.7%) 
were males with females accounting for only 45.3% of the group that had normal CRP levels. There was a significant 
association (p=0.001) between gender and CRP levels. In the group that had normal CRP levels, the highest 
proportion (47.2%) had a normal BMI. However, 28.3% of the group were overweight and 17% were obese. In the 
group that had elevated CRP levels, 41.5% were obese and 20.0% had a normal BMI. There was a significant 
association (p=0.001) between BMI and CRP levels. In the group that had normal CRP levels, the highest proportion 
(90.6%) had normal total cholesterol. However, 9.4% of the group had high total cholesterol. In the group that had 
elevated CRP levels, the highest proportion (76.9%) had normal total cholesterol. However, 23.1% of the group had 
high total cholesterol. This data revealed a significant association (p=0.033) between total cholesterol and CRP 
levels.  
 
In the group that had normal CRP levels, 81.1% were non-diabetic. However,18.9% of the group were diabetic. In 
the group that had elevated CRP levels, the highest proportion (65.1%) were non-diabetic whereas 34.9% were 
diabetic. There was a statistically significant link (p=0.033) between diabetes and CRP levels. A large percentage 
of the participants (87.4%) (p=0.868) tested HIV negative with 12.6% testing HIV positive in this study. The 
percentage who tested HIV positive was 14.9% in males and 11.2% in females.  However, statistically there was no 
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Table 2: Demographic and health factors of participants in this studyδ  
 Total Normal CRP* High CRP p-value 
Number of participants 183 53 (29%) 130 (71%)  
     
Gender    0.001 
Female  63.4 45.3 70.8  
Male 36.6 54.7 29.2  
Age group    0.482 
50-59 50.3 43.4 53.1  
60-69 35.5 39.6 33.8  
70+ 14.2 17.0 13.1  
Religion    0.399 
Christian 70.5 66.0 72.3  
Non-Christian 29.5 34.0 27.7  
Education    0.493 
Had no formal education 12.0 7.5 13.8  
Primary 44.8 47.2 43.8  
Secondary or higher 43.2 45.3 42.3  
Employed    0.486 
No 88.0 92.5 86.2  
Yes 6.6 3.8 7.7  
Retired 5.5 3.8 6.2  
Marital status    0.117 
Never 20.8 26.4 18.5  
Co-habiting 2.7 3.8 2.3  
Married 34.4 41.5 31.5  
Separate, divorced or widowed 42.1 28.3 47.7  
Smoking    0.506 
Never 73.2 69.8 74.6  
Ever 26.8 30.2 25.4  
Alcohol use    0.235 
Never 80.9 75.5 83.1  
Ever 19.1 24.5 16.9  
Income    0.984 
Other 23.5 22.6 23.8  
Govt grant 71.0 71.7 70.8  
None 5.5 5.7 5.4  
Add salt to food    0.088 
Never 35.5 35.8 35.4  
Always 14.8 18.9 13.1  
Rarely 48.6 41.5 51.5  
Don’t know 1.1 3.8 0.0  
Days in a week eat fruits    0.599 
0 days 4.9 1.9 6.2  
1-2 days 30.6 35.8 28.5  
3-4 days 38.3 39.6 37.7  
5-7 days 19.1 15.1 20.8  
Don’t know 7.1 7.5 6.9  
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Vigorous exercise    0.687 
Never 80.9 75.5 83.1  
Always 6.0 7.5 5.4  
Rarely 9.8 13.2 8.5  
Don’t know 3.3 3.8 3.1  
Body Mass Index (BMI    0.001 
Normal 27.9 47.2 20.0  
Under 6.6 7.5 6.2  
Over 31.1 28.3 32.3  
Obese 34.4 17.0 41.5  
Blood pressure    0.984 
Normal 11.5 5.7 13.8  
Prehypertensive 51.9 43.4 55.4  
Hypertensive 36.6 50.9 30.8  
Total Cholesterol    0.033 
Normal 80.9 90.6 76.9  
High 19.1 9.4 23.1  
Albuminuria    0.793 
Normal 82.0 79.2 83.1  
Micro 13.7 15.1 13.1  
Macro 4.4 5.7 3.8  
Diabetes    0.033 
Non-diabetic 69.8 81.1 65.1  
Diabetic 30.2 18.9 34.9  
HIV status    0.868 
Negative 87.4 86.8 87.7  
Positive 12.6 13.2 12.3  
 
δ Table presents percentage distributions in each column based on the number of participants in the table header as 
the denominator.  
* CRP levels were categorised as: CRP<1.0 mg/L as low, CRP 1.0-3.0 mg/L intermediate, and CRP>3.0 mg/L 
high / elevated. These were then recategorized as Normal (low and intermediate) and High (high/elevated), as 
presented in this table.  
  
4.1.2 COMPARISON OF C-REACTIVE PROTEIN LEVELS   
Serum CRP levels on the Alere AfinionTM AS100 ranged from <5mg/L to 45mg/L. The Alere AfinionTM 
AS100 median values for CRP were 9.5mg/L (25th percentile 6.5, 75th percentile 14.5) and 11.5mg/L (25th 
percentile 7.0, 75th percentile 19.0) in women and men respectively (p-value = 0.275). The ABX Pentra 400 
median levels were lower with 5.6mg/L (25th percentile 3.6, 75th percentile 9.2) and 3.6mg/L (25th percentile 
1.6, 75th percentile 8.3) for women and men (p-value = 0.027), respectively. CRP levels, shown as medians 
with minimum and maximum CRP values, were distributed across a wide range on both the Alere AfinionTM 
AS100 and ABX Pentra 400 analysers (Figure 14).  
Median CRP levels were slightly higher on the Afinion across all ages. However, median values for males on 
the Afinion were slightly higher compared to median values for males on the ABX Pentra 400. The ABX 
Pentra 400 showed a wider range of detection and Alere AfinionTM AS100 a narrower range of detection. 
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Figure 14: Comparison of C-reactive protein (CRP) levels by age and gender. Data are shown as medians 
(25th and 75th percentile) with minimum and maximum CRP values.  
 
When comparing CRP levels across different ethnic groups, it was found that the CRP levels on the Alere AfinionTM 
AS100 were slightly higher in African females compared to Indian females (Figure 15A). Whereas Indian males 
showed a wider distribution of the CRP levels using the ABX Pentra 400 (Figure15B). African female CRP levels 
on the Alere AfinionTM AS100 were shown to be on the higher levels whereas there was no difference in median 
values between Africans and Indians males on the Alere AfinionTM AS100. Both races had a median CRP value of 
10mg/L which was similar to median values seen on the ABX Pentra 400 with a 0.3mg/L difference between races. 
The ABX Pentra 400 had a wider range of detection and the Alere AfinionTM AS100 a narrower range of detection. 
Figure 14A shows that CRP levels on the Alere AfinionTM AS100 were slightly higher in African Females compared 
to Indian females. Indian males showed a wider distribution of the CRP levels using the ABX Pentra 400 (Figure 
15B).  
   A 
B    
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 Figure 15: Comparison of C-reactive protein (CRP) levels by race and gender. Data is shown as medians 
(25th and 75th percentile) with minimum and maximum CRP values.  
 
4.2 DIAGNOSTIC PERFROMANCE OF THE AFINION WHEN COMPARED TO THE 
PENTRA 400 
Lin’s correlation coefficients were used to assess the agreement between the Alere AfinionTM AS100 and the ABX 
Pentra 400 analysers (Table 3). Since the Alere AfinionTM AS100 has a measuring range 5-200mg/L, with any 
readings below 5mg/L simply labelled as <5mg/L. The Afinion identified 89 samples as low (<5mg/L), these cases 
with readings marked as <5mg/L on the Alere AfinionTM AS100 were excluded from the correlation analyses 
reducing the total number of samples to 94.   
  
Table 3: Differences between the Alere AfinionTM AS100 and ABX Pentra 400 CRP measurements using 
Bland-Altman (BA) Plots and Lin’s concordance correlation coefficients  
Table 3 presents differences between the Alere Afinion AS100 and ABX Pentra 400 CRP  
Abbreviations: SD- Standard Deviation, BA- Bland- Altman  
 
CRP  N  Mean  bias  
(SD)  
95% BA Limits of 
Agreement   
Concordance 
correlation   
95% Confidence  
Interval  
Overall  94  1.323 (1.558)  (-1.731; 4.378)  0.977  (0.969; 0.985)  
 
Mean bias is the average difference between CRP measurements on the Afinion and the Pentra. Most of the 
differences between the two methods would be expected to be between minus 2 standard deviation (SD) and plus 2 
SD. In our analysis, the standard deviation of the mean bias was plus 1.558.  
The Bland Altman (BA) limits of agreement gives the differences between the CRP measurement on the Afinion 
compared to the measurement for the same participant on the Pentra. From the table above, this means 95% of the 
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measurements on the Afinion were from 1.731 below the Pentra measurement to 4.378 above the Pentra 
measurements.  
 
Figure 16 shows the Bland Altman plot comparing mean difference in the CRP estimations from the Afinion to the 
Pentra 400 method. The purple solid line represents the mean difference in CRP concentrations between the two 
methods, whereas the red lines represent 95% confidence limits of the agreement. The line y=0 is where all values 
would lie if there was perfect agreement between the Alere AfinionTM AS100 and the ABX Pentra 400 CRP 
concentrations. The Bland Altman CRP two-way scatter plot shown in Figure 16 indicated that the Alere AfinionTM 
AS100 gave slightly higher CRP readings than the ABX Pentra 400, with a mean difference of 1.323 (SD 1.558). 
In only a few cases did the Alere AfinionTM AS100 give a lower reading than the ABX Pentra 400 (scatter points 
below zero).  
The proportion of CRP results from the remaining sample that were correctly classified by the Alere AfinionTM 
AS100 analyser was 95.07%. Bland-Altman analysis and linear regression analysis showed an excellent correlation 
between the two analysers, with a correlation concordance 0.977 between the two analysers for the measurement of 
CRP. This excellent correlation is further illustrated in Figure 17, which shows nearly all the values from the Alere 
AfinionTM AS100 and the ABX Pentra 400 lying perfectly on the regression line (solid black line) not far away from 
the line of perfect concordance (dashed red line) (Figure 17). The Alere AfinionTM AS100 was able to identify 44 
samples with CRP measurements above 10mg/L compared to the 38 identified by the ABX Pentra 400. Six samples 

















Figure 17: Regression analysis of CRP values produced from the Alere AfinionTM AS100 (A) and ABX Pentra 
400 (P) analysers. 
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4.3 C-REACTIVE PROTEIN – EVALUATION OF BIAS  
Although excellent correlation was shown between the Alere AfinionTM AS100 and the ABX Pentra 400 analysers 
there were some differences in the distribution of the results obtained by the two analysers. The results from the 
Alere AfinionTM AS100 were from <10mg/L to >40mg/L as compared to ABX Pentra 400 results that were 
distributed from <10mg/L up to >60mg/L. The mean bias observed for the CRP measurements between the Alere 
AfinionTM AS100and the ABX Pentra 400 was 1.323 (1.558) with the 95% BA Limits of Agreement of (1.731; 
4.37).  
 
4.4 RISK FACTORS ASSOCIATED WITH CRP LEVELS  
The data obtained for the risk factors were obtained from the parent study. In the univariate analysis (Table 4), being 
obese (Odds Ratio [OR]: 1.98, 95% Confidence Interval [CI]: 1.3616, 2.889, p<0.001) and having low HDL levels 
(OR: 1.64, 95% CI: 1.158, 2.307, p= 0.005) were the only risk factors that were statistically significantly associated 
with increased likelihood of having elevated CRP levels. Whereas being male (p=0.041); aged ≥60 years (p=0.048); 
being pre-hypertensive (p=0.018); and being hypertensive (p=0.002) were all associated with statistically significant 
lower odds ratios of having elevated CRP.  
 
The association with not being at risk of elevated CRP with being pre-hypertensive was also shown in the 
multivariate analysis (p=OR: 0.52, 95% CI: 0.313, 0.868, p=0.013). Similarly, being hypertensive was significant 
in the univariate (OR: 0.45, 95% CI: 0.274, 0.752, p=0.002) and multivariate analysis (OR: 0.39, 95% CI: 0.220, 
0.680, p=0.001) as a non-risk factor. In the multivariate analysis (Table 5), being obese (OR:  
2.58, 95% CI: 1.616, 4.120, p<0.001) and low HDL levels were sustained as risk factors (OR: 1.42, 95% CI:  
0.999, 2.016, p=0.050). An additional risk factor identified in the multivariate analysis was HIV positivity (OR: 
1.66, 95% CI: 1.004, 2.741, p=0.048). In the univariate analysis, the odds for Indians to have elevated CRP was 
1.15 times higher than for black Africans, whereas in the multivariate analysis Indians had an odds ratio of 0.99 
compared to black Africans. However, both findings were not statistically significant (p= 0.847 and 0.948, 
respectively). Associations of age with CRP were conflicting. In the univariate analysis participants aged 60 years 
and over were less likely to have elevated CRP levels and this was statistically significant (OR: 0.74, 95% CI: 0.545, 
0.998, p= 0.048). Although in the multivariate analysis those aged ≥60 years were still less likely to have elevated 
CRP levels, however, this was not statistically significant (OR: 0.89, 95% CI: 0.640, 1.235, p=0.481).   
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Table 4: Univariate analysis of factors associated with Elevated CRP levels in older adults δ 
 
 OR    [95 %  CI]    p -value  
Gender         
Female  1.00     
Male  0.72    0.5275    0.9871    0.041    
  
Race  
       
Black   1.00     
Indian   1.15    0.8466    1.5692    0.365    
  
Age group  
       
<60  1.00     
≥60 years  0.74    0.5453    0.9978    0.048    
  
Education  
       
Never been to school  1.00     
Primary  0.66  0.4001  1.0728  0.092  
Secondary+  0.77    0.4671    1.2574    0.290    
  
Adds salt when cooking  
       
Never  1.00     
Always  0.93  0.5792  1.4938  0.763  
Rarely  1.05  0.7500  1.4732  0.771  
Don’t know  0.47    0.1056    2.0592    0.312    
  
Smoking  
       
Non-smoker  1.00     
Smoker  1.04    0.7346    1.4639    0.836    
  
Alcohol consumption  
       
Non-drinker  1.00     
Alcohol drinker  0.78    0.5329    1.1546    0.217    
  
Vigorous activity/exercise  
       
Never  1.00     
Always  0.71  0.3720  1.3501  0.293  
Rarely   0.76  0.4518  1.2651  0.285  
Don’t know  0.71    0.3003    1.6733    0.430    
  
Hypertension  
       
Normal  1.00     
Prehypertensive  0.55  0.3403  0.9009  0.018  
Hypertensive  0.45    0.2743    0.7529    0.002    
  
BMI 
       
Normal  1.00     
Underweight  1.18  0.6193  2.2312  0.619  
Overweight  1.20  0.8186  1.7679  0.345  
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Obese  1.98    1.3616    2.8896    <0.001    
      
Total cholesterol         
TC Normal  1.00     
TC elevated  1.01    0.6865    1.4921    0.952    
  
HDL cholesterol  
       
HDL Normal   1.00     
HDL Low  1.64    1.1586    2.3075    0.005    
  
LDL cholesterol  
       
LDL Normal  1.00     
LDL elevated  0.92    0.6629    1.2771    0.617    
  
Albuminuria  
       
Albumin Normal  1.00     
Micro Albuminuria  0.95  0.6091  1.4899  0.831  
Macro Albuminuria  1.08    0.5102    2.2928    0.837    
  
HIV status  
       
HIV negative  1.00     
HIV positive  1.25  0.7924  1.9858  0.332  
  
 δ Table 4 presents univariate analysis of factors associated with Elevated CRP levels in older adults  
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Table 5: Multi-variable analysis of factors associated with Elevated CRP levels in older adults δ   
  
 OR    [95 %  CI]    p -value  
 
Gender  
        
Female      
Male  0.85    0.5606    1.2756    0.422    
  
Race  
        
Black African      
Indian African  0.99    0.6748    1.4449    0.948    
  
Age group  
        
<60      
≥60 years  0.89    0.6402    1.2347    0.481    
  
Education  
        
Never been to school      
Primary  0.81  0.4969  1.3363  0.415  
Secondary+  0.92    0.5497    1.5272    0.736    
  
Adds salt when cooking  
        
Never      
Always  1.03  0.6520  1.6420  0.884  
Rarely  1.10  0.7945  1.5293  0.558  
Don’t know  0.59    0.1331    2.6317    0.489    
  
Smoking  
        
Non-smoker      
Smoker  1.25    0.8301    1.8779    0.284    
  
Alcohol consumption  
        
Non-drinker      
Alcohol drinker  0.98    0.6334    1.5234    0.936    
  
Vigorous activity/exercise  
        
Never      
Always  0.88  0.4552  1.7156  0.713  
Rarely   0.89  0.5378  1.4692  0.644  
Don’t know  0.79    0.3401    1.8458    0.587    
  
Hypertension  
        
Normal      
Prehypertensive  0.52  0.3137  0.8682  0.013  
Hypertensive  0.39    0.2209    0.6809    0.001    
  
Obesity  
        
Normal      
Underweight  1.07  0.5538  2.0643  0.841  
Overweight  1.55  1.0041  2.3997  0.048  
Obese  2.58    1.6163    4.1203    <0.001    
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Total cholesterol  
        
TC Normal      
TC elevated  0.84    0.5410    1.3180    0.454    
  
HDL cholesterol  
        
HDL Normal       
HDL Low  1.42    0.9999    2.0164    0.050    
  
LDL cholesterol  
        
LDL Normal      
LDL elevated  1.00    0.6916    1.4504    0.993    
  
Albuminuria  
        
Albumin Normal      
Micro Albuminuria  1.00  0.6343  1.5693  0.992  
Macro Albuminuria  1.91    0.8883    4.1091    0.097    
  
HIV status  
        
HIV negative      
HIV positive  1.66  1.0044  2.7419  0.048  
  
 δ Table 5 presents Multi-variable analysis of factors associated with Elevated CRP levels in older adults    
    Factors: Diabetes, high total cholesterol, obesity and hypertension.  
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            CHAPTER FIVE   
5.1 DISCUSSION   
C-reactive protein is a vital biomarker of inflammation which is used to detect cardiovascular diseases in patients 
at high risk (Lee et al, 2014). CRP has been demonstrated by several studies to be an independent predictor of future 
risk for cardiovascular events among healthy individuals, including patients with acute coronary syndromes 
(Shrivastava et al., 2015). Lipid screening is currently used to detect cardiovascular events and to make clinical 
decisions in terms of patient treatment, care and management (Sproston et al., 2018). However, it has been reported 
that almost half of cardiovascular events occur in individuals with low to average levels of low-density lipoprotein 
cholesterol (Clearfield, 2005). The incorporation of CRP levels into standard cholesterol assessment protocols adds 
value by aiding the clinicians’ ability to predict CVD risk (Clearfield, 2005).  
The current study evaluated the performance of the Alere AfinionTM AS100 analyser in comparison with the 
standard laboratory method, the ABX Pentra 400 for the quantification of CRP. This evaluation was performed in 
a population of HIV positive and negative older adults. The results of the Bland Altman plots showed that overall, 
the correlation of the Alere AfinionTM AS100 against the Pentra 400 for the measurement of CRP levels was very 
good, making it a good POC analyser for the measurement of CRP. However, this is only true for CRP levels 
>5mg/L. In addition, our sample size was very small (about 50% of the original sample) which limits us from 
making strong recommendations regarding the AS100 Analyser. Our findings are supported by other published 
studies. A study by Minnaard et al., 2013, evaluated 5 CRP POCT devices (Afinion™, NycoCard™ reader II, 
Eurolyser Smart 700/340, QuikRead go®, QuikRead®). The study by Minnaard et al., 2013 revealed that at the 
intermediary concentration of (20-100mg/L), the Afinion™ was the most accurate device. The authors concluded 
that the Afinion™ showed better agreement when compared to the other 3 POCTs. The agreement between the 
POCT and the laboratory standard decreased at higher CRP concentrations, resulting in wider confidence intervals 
around the mean differences at CRP concentrations greater than 100mg/L.   
 Alere Afinion™ AS100 analyser is capable of testing multiple analytes such as HbA1C and albumin creatinine 
ratio (ACR). Imprecision results showed the Alere Afinion™ AS100 ACR test to be a precise POCT analysis. 
Available data revealed that Alere Afinion™ AS100 ACR test provided a three in one POCT for the measurement 
of albumin, creatinine and ACR in one specimen within only less than an hour 5minutes 35seconds to be precise 
(Kvam et al., 2009). 
Results of the three analytes might be measured concurrently using one patient specimen. The ACR assay presented 
simultaneously performs the analysis of samples for both albumin and creatinine. The creatinine reaction is 
completed within 4minutes, utilizing the advanced end point prediction algorithm, while the albumin assay, 
launched just after the creatinine reaction, takes approximately 3 minutes. Both assays run in parallel and result in 
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The Alere Afinion™ AS100 is a simple, robust, convenient and safe analyser (Kvam et al., 2009). This study showed 
that the Alere Afinion™ AS100 would be able to provide reliable, fast patient results leading to speedy medical 
decisions taken by clinicians. However, these are our assumptions and yet to be evaluated. A fast turnaround time 
that would further improve interaction between patients and the clinic staff. Ivaska et al., 2015 compared the Alere 
Afinion™ AS100 CRP POC analyser to the CRP test (Modular P, Roche Diagnostics). The study focused more on 
febrile children at the emergency department with median age 2.4 years. In this study, the Alere Afinion™ AS100 
showed a good correlation with the reference method. Verbakel et al., 2013 provided further evidence on the 
analytical accuracy of the Alere Afinion™ AS100 POC CRP test. The Alere Afinion™ AS100 was compared with 
an immunoturbidimetric CRP test, the Cobas c702 analyser in children and adults. The study confirmed that the 
few variations observed between the methods did not interfere with the clinical decision on patient care or 
management. These variations were deemed as of clinical insignificance. CRP measurements using the Alere 
Afinion™ AS100 CRP showed a high correlation even at high CRP measurements. This analytical accuracy 
contributed to the consensus amongst all physicians and investigators that had participated in this study to conclude 
the user-friendliness of the Alere Afinion™ AS100. Results from the study on sexual health and chronic morbidities 
in people aged ≥50 years which was conducted in the Chatsworth and Botha’s Hill areas in Durban, South Africa, 
revealed that an urgent intervention to address the issue of increasing challenges of HIV and non-communicable 
disease among older adults is required (Abbai et al., 2018).   
  
In the study by Brouwer et al., 2015, eight analysers (Actim; Cleartest, AfinionTM, Eurolyser Smart, Ichroma, 
Microsemi, AQT90 FLEX) were evaluated for accuracy (agreement, bias, correlation precision (CV) and ease of 
use. The Alere Afinion™ AS100 was one of the few analysers that showed a good correlation. Brouwer et al., 2015 
performed a comparison study of the six quantitative POCT devices (QuikRead go, Smart Eurolyser, Afinion™, 
ichroma™, Microsemi) and two semi-quantitative methods to measure CRP. A practical evaluation for the six 
analysers was performed in a laboratory setting, where the main aim of the study was to evaluate the minimum 
amount of material required, analytical range, pre-analytical handling of the samples and estimated pre-analytical 
time, if haematocrit (HCT) correction was required, size and weight of the analyzer, and whether the device was 
also able to measure other analytes. In this evaluation it was concluded that the Alere Afinion™ AS100 required 
the least pre-analytical handling which was less than a minute and the Alere Afinion™ AS100 and the Eurolyser 
were concluded as the preferred analysers for CRP POCT (Brouwer et al., 2015). These six devices all use capillary 
blood samples. Brouwer et al., 2015 concluded that when combining analytical performance and practical 
evaluation, the Alere Afinion™ AS100 and the Smart Eurolyser gave the best agreement and were concluded to be 
the preferred POCT analysers.   
 
 In this study, we looked at potential risk factors for CVDs in association with CRP levels.  We found that 34.4% 
(P=0.001) of participants were obese according to the BMI calculations taken in this analysis. Evidence that obesity 
and even excessive weight have a close association with an elevated risk of CVDs has been shown by Imre et al., 
2018. According to Lavie et al., 2009, obesity presents many adverse effects on the functioning of the cardiovascular 
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structure. In addition, obesity tends to increase total blood volume and cardiac input causing cardiac workload to 
be greater than usual. Evidence from the study on the association between obesity and cardiovascular outcomes by 
Haris et al., 2018 also revealed that obesity is associated with CVDs.  Evidence has also shown that the mortality 
and morbidity of CVDs is increased in individuals who are overweight (Van Gaal et al., 2006).  
Findings from our study are on par with other studies with regards to the association of obesity with the risk of 
elevated CRP and thus by correlation with increased risk of CVDs. Findings from other studies revealed that high 
cholesterol was prevalent among adults in Africa (Noubiap et al., 2018). Harris et al., 2017, concluded that increased 
cholesterol was one of the confirmed risk factors for CVDs. Walker et al., 2001 further confirmed that the prevalence 
of high total cholesterol and other CVD risk factors in the South African population was evident and there is a high 
probability that the growing urbanisation of the black African population may cause this prevalence to increase. 
Seedat et al., 2011 also confirmed that high total cholesterol is a major CVD risk factor in South Africans and that 
it is found in all population groups in South Africa. Our study was able to demonstrate that being obese (Odds Ratio 
[OR]: 1.98, 95% Confidence Interval [CI]: 1.3616, 2.889, p<0.001) and having low HDL levels (OR: 1.64, 95% 
CI: 1.158, 2.307, p= 0.005) were the only significant risk factors that were associated with elevated CRP levels in 
the studied population. Something that has been previously shown, which our results were unable to demonstrate, 
was that having a low level of the good high-density lipoprotein (HDL) was a significant risk fact for having elevated 
CRP. However, further studies in the older population are needed to collaborate these findings for a nuanced 
understanding of the contribution of low HDL to cardiovascular disease risk in adult populations.   
 
The study by Matthew et al., 2008 suggested that the presence of atherosclerosis caused by a condition such as HIV 
and its treatment have a high effect in increasing the risk of CVDs among people who are infected with HIV. Some 
observational cohort studies have also demonstrated increased levels of CVDs such as CHD or AMI in HIV-infected 
versus control patients, with an approximate 1.5 to 2-fold increased relative risk (Klein et al., 2002; Currier et al., 
2003; Triant et al., 2007; Lang et al., 2010; Durand et al., 2011).  
 
A study on HIV, hypertension and CVDs by Spencer, 2016 revealed that there is a close link between HIV infection 
and increased risk of CVDs. Other studies have also revealed that specific antiretroviral drugs, such as abacavir, 
indinavir and lopinavir may increase risk for CVDs (Bavinger et al., 2013). These studies further confirmed that 
HIV infected individuals are at high risk of developing CVDs (Bavinger et al., 2013; Triant, 2013). The study 
investigated the link between hospitalization for severe infection and consequent risk of CVD in a large, well-
characterized cohort of HIV-infected individuals in a middle-income country.  
The study also revealed that after controlling for traditional and HIV-related CVD risk factors, the incidence of 
severe infection was associated with an elevated CVD risk in the year subsequent to hospital discharge. 
Furthermore, the study detected that this link was time-dependent, greater within the first 3 months after hospital 
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5.2 LIMITATIONS OF THE STUDY  
The manufacturer claims that the CRP reference range for adults (20-60 years) is < 5mg/L. This reference range did 
not cater for 14.2% of the study population of participants aged above 70 years of age. Stored samples were used 
for the evaluation of the Alere Afinion™ AS100 for the measurement of the CRP, which may not provide as similar 
readings as using fresh samples. Our findings, however, showed a good correlation between the Alere Afinion™ 
AS100 analyser and the standard laboratory analyser, the ABX Pentra 400, suggesting the reliability of these 
findings. Abdominal obesity has been indicated to be a worldwide risk factor for CVDs. In addition, over and above 
CVD, obesity has been revealed to increase the risk of high blood pressure (Din-Dzietham et al., 2007). However, 
in the parent study, no data was collected on waist circumference and this was another limitation in the parent study. 
Our study did not have a good representation with regards to HIV infection as this was a population with only 12.6% 
HIV-positive individuals, so the prevalence is not significantly high. 
 
There is thus sufficient evidence to show that the Alere Afinion™ AS100 may be a good POC analyser for screening 
in older adults within a high HIV prevalence setting. However, another major limitation of this study is the fact that 
nearly 50% of the sample could not be used in the concordance correlations due to the AfinionTM not being able to 
detect values lower than 5mg/L.This substantially reduces statistical power, making it extremely difficult to draw 
conclusions. 
 
5.3 CONCLUSION  
Presently there is lack of data on POCTs for the measurement of CRP levels, especially in older South African 
persons. This study was the first to evaluate the performance of the Alere Afinion™ AS100 in the quantification of 
CRP in a population of HIV negative and HIV-positive adults from the age of 50 years and above in a high HIV 
setting. It was also the first study to evaluate the diagnostic performance of the Alere Afinion™ AS100 analyser 
compared to the ABX Pentra 400 analyser (reference test) in measuring levels of CRP in an older South African 
population. Though the Alere Afinion™ AS100 was found to be comparable to the reference test, it would not add 
much value in detecting high risk patients as it can only detect CRP levels from 5mg/L and above. Patients with 
CRP levels below 5mg/L would be missed despite possibly being at high risk  
 
In addition, the data generated from this study provided insights regarding the association of elevated CRP and 
various CVD risk factor conditions which will facilitate better patient management. The results of the study revealed 
that the Alere Afinion™ AS100 can be used as a POCT for the measurement of CRP to detect CRP levels from 
5mg/L and above.  
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  APPENDICES 
This section contains examples of documents used during the study, Specimen Storage Protocols, Pictorial views 
of equipment used during the study, results of the samples tested during the study.  It also contains copies of the 
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APPENDIX 2:  INFORMED CONSENT (IC) (STORAGE AND FUTURE TESTING OF                              
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APPENDIX 5: MEDICAL RESEARCH COUNCIL ACCESS TO STORED SAMPLES                          
APPROVAL  
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APPENDIX 8: SAMRC HPRU CONCEPT FORM   
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APPENDIX 9: STUDENT SPECIFIC STUDY CHECKLIST  
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APPENDIX 10:  LABORATORY RESULTS Table CRP TEST RESULTS–SAMPLES 001- 184  
  
CRP test results for older adults, South Africa  
PTID  CRP_Pentra  CRP_Afinion  Mean CRP  Mean difference   
30816253  6.2  5  5.6  0.6  
30816254  
30816257  
6.9  7  6.95  -0.05  
12.2  14  13.1  -0.9  
30816259  5.1  6  5.55  -0.45  
30816260  
30816261  
11.3  14  12.65  -1.35  
35.9  43  39.45  -3.55  
30816265  9  9  9  0  
30816266  15  17  16  -1  
30816267  
30816268  
5.8  8  6.9  -1.1  
14.6  16  15.3  -0.7  
30816269  8.4  8  8.2  0.2  
30816270  11.7  12  11.85  -0.15  
30816271  17.2  22  19.6  -2.4  
30816273  
30816274  
22.5  22  22.25  0.25  
27.3  29  28.15  -0.85  
30816275  9.9  11  10.45  -0.55  
30816279  5.6  6  5.8  -0.2  
30816281  9.9  10  9.95  -0.05  
30816282  
30816285  
10  10  10  0  
7.7  8  7.85  -0.15  
30816289  4.6  6  5.3  -0.7  
30816291  5.1  6  5.55  -0.45  
30816293  
30816294  
6.5  7  6.75  -0.25  
16.6  21  18.8  -2.2  
30816295  25.2  33  29.1  -3.9  
30816296  6.1  8  7.05  -0.95  
30816297  
30816298  
8.2  11  9.6  -1.4  




7.2  10  8.6  -1.4  
9.1  11  10.05  -0.95  
5  6  5.5  -0.5  
30816305  4.1  5  4.55  -0.45  
30816308  8.3  11  9.65  -1.35  
30816309  43.8  44  43.9  -0.1  
30816310  
30816311  
16  19  17.5  -1.5  
4.9  6  5.45  -0.55  




17.3  19  18.15  -0.85  
11.1  12  11.55  -0.45  
6  7  6.5  -0.5  
30816320  42.5  45  43.75  -1.25  
 




13.9  14  13.95  -0.05  





37.6  41  39.3  -1.7  
16.8  18  17.4  -0.6  
7.3  8  7.65  -0.35  
30816333  5.8  6  5.9  -0.1  
30816336  6.2  6  6.1  0.1  
30816339  5.6  6  5.8  -0.2  




8.4  9  8.7  -0.3  
7.1  7  7.05  0.05  
20.7  24  22.35  -1.65  
30816356  7.9  9  8.45  -0.55  
30816357  15  17  16  -1  
30816358  
30816359  
11.8  11  11.4  0.4  
8.6  9  8.8  -0.2  
30816362  5.6  6  5.8  -0.2  
30816363  6.3  6  6.15  0.15  
30816366  5.3  5  5.15  0.15  
30816368  11.4  13  12.2  -0.8  
30816369  6.2  6  6.1  0.1  
30816370  
30816371  
9.3  10  9.65  -0.35  
7  8  7.5  -0.5  
30816372  6.8  7  6.9  -0.1  
30816377  
30816379  
7.3  9  8.15  -0.85  
6.2  6  6.1  0.1  
30816382  13.7  14  13.85  -0.15  




12.2  13  12.6  -0.4  
6.3  6  6.15  0.15  
23.9  24  23.95  -0.05  
30816392  
30816394  
5.3  6  5.65  -0.35  
6.2  7  6.6  -0.4  
30816396  15.6  19  17.3  -1.7  
30816400  
30816401  
7  8  7.5  -0.5  




13.3  15  14.15  -0.85  
5.6  6  5.8  -0.2  
9.7  12  10.85  -1.15  
30816411  7  10  8.5  -1.5  
30816415  
30816416  
23.5  26  24.75  -1.25  
10.4  12  11.2  -0.8  
30816417  10.1  11  10.55  -0.45  
30816418  5.2  6  5.6  -0.4  
30816420  8.6  10  9.3  -0.7  
 





9.1  9  9.05  0.05  
3  32  17.5  -14.5  
16.4  17  16.7  -0.3  
30816427  5.4  5  5.2  0.2  




7.6  8  7.8  -0.2  
14.3  18  16.15  -1.85  
13.2  15  14.1  -0.9  
Total mean  12.02  13.63      
NB: For samples where CRP_Afinion is greater or equal to five (measuring range of Afinion AS100 analyser).   
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CRP test results for older adults, South Africa Continued   
PTID  CRP_Pentra  CRP_Afinion  Mean CRP  Mean difference   
30816252  
30816255  
1.9  <5  1.9  0  
2.6  <5  2.6  0  
30816258  0.4  <5  0.4  0  
30816262  0.5  <5  0.5  0  
30816263  3.2  <5  3.2  0  
30816264  
30816272  
4.2  <5  4.2  0  
5.3  <5  5.3  0  
30816276  3.8  <5  3.8  0  
30816277  2.5  <5  2.5  0  
30816278  1.3  <5  1.3  0  
30816280  
30816283  
2  <5  2  0  
3.4  <5  3.4  0  
30816284  2.8  <5  2.8  0  
30816286  1.6  <5  1.6  0  
30816287  2.1  <5  2.1  0  
30816288  
30816290  
3.8  <5  3.8  0  




0.7  <5  0.7  0  
1.8  <5  1.8  0  
9.1  <5  9.1  0  
30816304  
30816306  
2.3  <5  2.3  0  
3.4  <5  3.4  0  
30816307  0.1  <5  0.1  0  
30816315  1.3  <5  1.3  0  
30816316  
30816317  
1.7  <5  1.7  0  
1.5  <5  1.5  0  
30816318  1.2  <5  1.2  0  
30816321  
30816322  
1.9  <5  1.9  0  
1.6  <5  1.6  0  
30816324  4  <5  4  0  
30816326  
30816327  
2.2  <5  2.2  0  
4.4  <5  4.4  0  
30816328  1.6  <5  1.6  0  
30816330  
30816334  
4.9  <5  4.9  0  
1.1  <5  1.1  0  
30816335  0.3  <5  0.3  0  
30816337  
30816338  
3.3  <5  3.3  0  
5.3  <5  5.3  0  




2.3  <5  2.3  0  
2.2  <5  2.2  0  
1.9  <5  1.9  0  
30816346  3.6  <5  3.6  0  
30816347  3.8  <5  3.8  0  
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2.9  <5  2.9  0  
5.4  <5  5.4  0  
2.4  <5  2.4  0  
30816354  2.1  <5  2.1  0  
30816355  4.4  <5  4.4  0  
30816360  1.7  <5  1.7  0  




1  <5  1  0  
0.3  <5  0.3  0  
2  <5  2  0  
30816373  1.4  <5  1.4  0  
30816374  1.8  <5  1.8  0  
30816375  
30816376  
1.4  <5  1.4  0  
3.3  <5  3.3  0  
30816378  2.1  <5  2.1  0  
30816380  2.3  <5  2.3  0  
30816381  5  <5  5  0  
30816384  4  <5  4  0  
30816385  0.3  <5  0.3  0  
30816386  
30816388  
4.1  <5  4.1  0  
4.7  <5  4.7  0  
30816391  4.5  <5  4.5  0  
30816393  
30816395  
0.7  <5  0.7  0  
3.4  <5  3.4  0  
30816397  0.5  <5  0.5  0  




2.1  <5  2.1  0  
3.1  <5  3.1  0  
2.5  <5  2.5  0  
30816404  
30816405  
3.9  <5  3.9  0  
3.1  <5  3.1  0  
30816409  0.6  <5  0.6  0  
30816410  
30816412  
1.3  <5  1.3  0  




4.8  <5  4.8  0  
0.8  <5  0.8  0  
2.4  <5  2.4  0  
30816423  2.2  <5  2.2  0  
30816424  
30816426  
1  <5  1  0  
4.2  <5  4.2  0  
30816428  4.9  <5  4.9  0  
30816433  4  <5  4  0  
30816434  3  <5  3  0  
30816435  
Total mean  
4.5  <5  4.5  0  
2.67  NA      
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APPENDIX 12: AFINION AS100 INTERNAL QUALITY CONTROL FORM 
 
 
